folder

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Authors

  • L.A. Völker
  • J. Kaufeld
  • W. Miesbach
  • S. Brähler
  • M. Reinhardt
  • L. Kühne
  • A. Mühlfeld
  • A. Schreiber
  • J. Gaedeke
  • M. Tölle
  • W.J. Jabs
  • F. Özcan
  • S. Markau
  • M.. Girndt
  • F. Bauer
  • T.H. Westhoff
  • H. Felten
  • M. Hausberg
  • M. Brand
  • J. Gerth
  • M. Bieringer
  • M. Bommer
  • S. Zschiedrich
  • J. Schneider
  • S. Elitok
  • A. Gawlik
  • A. Gäckler
  • A. Kribben
  • V. Schwenger
  • U. Schoenermarck
  • M. Roeder
  • J. Radermacher
  • J. Bramstedt
  • A. Morgner
  • R. Herbst
  • A. Harth
  • S.A. Potthoff
  • C. von Auer
  • R. Wendt
  • H. Christ
  • P.T. Brinkkoetter
  • J. Menne

Journal

  • Blood Advances

Citation

  • Blood Adv 4 (13): 3085-3092

Abstract

  • Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with initial disease presentation and in 4 additional patients with laboratory signs of an exacerbation or relapse after the initial therapy, PEX-free treatment regimens could be established with overall favorable outcome. Caplacizumab is efficacious in the treatment of aTTP independent of timing and ancillary treatment modalities. Based on this real-world experience and published literature, we propose to administer caplacizumab immediately to all patients with an acute episode of aTTP. Treatment decisions regarding the use of PEX should be based on the severity of the clinical presentation and known risk factors. PEX might be dispensable in some patients.


DOI

doi:10.1182/bloodadvances.2020001973